Background
Rocky Mountain spotted fever (RMSF) is a disease that now causes
significant morbidity and mortality on several American Indian reservations
in Arizona. Although the disease is treatable, reported RMSF case fatality
rates from this region are high (7%) compared to the rest of the
nation (<1%), suggesting a need to identify clinical points
for intervention.
Methods
The first 205 cases from this region were reviewed and fatal RMSF
cases were compared to nonfatal cases to determine clinical risk factors for
fatal outcome.
Results
Doxycycline was initiated significantly later in fatal cases (median,
day 7) than nonfatal cases (median, day 3), although both groups of case
patients presented for care early (median, day 2). Multiple factors
increased the risk of doxycycline delay and fatal outcome, such as early
symptoms of nausea and diarrhea, history of alcoholism or chronic lung
disease, and abnormal laboratory results such as elevated liver
aminotransferases. Rash, history of tick bite, thrombocytopenia, and
hyponatremia were often absent at initial presentation.
Conclusions
Earlier treatment with doxycycline can decrease morbidity and
mortality from RMSF in this region. Recognition of risk factors associated
with doxycycline delay and fatal outcome, such as early gastrointestinal
symptoms and a history of alcoholism or chronic lung disease, may be useful
in guiding early treatment decisions. Healthcare providers should have a low
threshold for initiating doxycycline whenever treating febrile or
potentially septic patients from tribal lands in Arizona, even if an
alternative diagnosis seems more likely and classic findings of RMSF are
absent.